Pulmonary/Respiratory Diseases | Preclinical Developments | UNITED KINGDOM

Nuformix

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme

Lead Product(s): NXP004

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: NXP004

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 19, 2020

Details:

NXP004 showed a dose-dependent reduction in the secretion of several key ECM components.These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model.

Redx Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Redx Signs Out Licensing Agreement With Astrazeneca

Lead Product(s): RXC006

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RXC006

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: AstraZeneca PLC

Deal Size: $377.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 04, 2020

Details:

Under the terms of the exclusive global agreement, AstraZeneca will take RXC006 forward into clinical development, targeting fibrotic diseases including idiopathic pulmonary fibrosis (IPF).

Immune Regulation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Immune Regulation and DynPort to Trial Covid-19 Drug Candidate

Lead Product(s): ILR201104

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ILR201104

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: DynPort

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 06, 2020

Details:

The Immune Regulation entered into a Teaming Agreement with DynPort Vaccine Company LLC to jointly evaluate the potential of Immune Regulation’s drug product ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.

Redx Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BE PHARMA 2020

Participation Not Confirmed

Update your events

Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis

Lead Product(s): RXC007

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

Details:

Preclinical data with compounds from Redx’s ROCK2 programme have demonstrated robust anti-fibrotic effects in a range of industry-standard in vivo models.

Find

Find Drugs for Pulmonary/Respiratory Diseases in Preclinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

Nuformix

Nuformix Reports Results from Pre-clinical Pilot Study in IPF for NXP004 Programme

Redx Pharma

Redx Signs Out Licensing Agreement With Astrazeneca

Immune Regulation

Immune Regulation and DynPort to Trial Covid-19 Drug Candidate

Redx Pharma

Redx Pharma nominates RXC007, a novel, orally active ROCK2 inhibitor as next drug development candidate in fibrosis